Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved tags : Biotech save search
5th Time’s the Charm: Graf Acquisition IV Shareholders Approve NKGen Biotech Merger on Unanimous Vote
Published: 2023-09-29 (Crawled : 21:00) - spacfeed.com
LXEO | $12.26 0.25% 1.92% 92K
|
| Email alert
Add to watchlist
biotech acquisition
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
Published: 2023-07-06 (Crawled : 21:00) - globenewswire.com
BWV | $0.1802 5.44% 530K
|
|
| O: 1.8%
H: 3.54%
C: 1.77%
water fda biotech state approved license blue
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Published: 2023-06-14 (Crawled : 12:00) - globenewswire.com
BWV | $0.1802 5.44% 530K
|
|
| O: 89.87%
H: 5.33%
C: -14.67%
water biotech six treatment commercial blue
AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval
Published: 2023-05-31 (Crawled : 17:00) - biospace.com/
BIIB | $192.16 -1.53% -1.57% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.3%
C: -0.76%
fda drug biotech approval
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
Published: 2023-05-19 (Crawled : 18:00) - globenewswire.com
KRYS | $169.64 -0.27% -0.42% 150K
|
Health Technology
|
| O: 1.34%
H: 9.81%
C: 8.4%
fda biotech approval treatment
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
EDSA | $4.4 1.25% -2.3% 570
|
Health Technology
|
| O: -0.67%
H: 1.85%
C: -5.37%
biotech approval study phase 2
Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment
Published: 2023-01-04 (Crawled : 00:00) - prnewswire.com
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: 0.3%
H: 0.0%
C: 0.0%
acquisition biotech extension approval trust
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
Published: 2022-06-03 (Crawled : 13:00) - biospace.com/
LEGN | $48.83 -2.57% -2.62% 1.4M
|
Health Technology
|
| O: 1.08%
H: 7.74%
C: 7.2%
lb1908 fda clearance biotech application pancreatic
Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination
Published: 2022-06-03 (Crawled : 02:00) - prnewswire.com
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: 6.09%
H: 1.54%
C: 1.44%
acquisition biotech therapeutics
Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: -1.11%
H: 3.71%
C: 1.69%
acquisition biotech therapeutics
Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
OACB | $9.38 0.0%
|
Finance
|
| O: 0.0%
H: 0.1%
C: -0.1%
acquisition biotech
MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -3.03%
H: 3.21%
C: 3.21%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 3.07%
H: 0.0%
C: 0.0%
thio-101 phase 2 technology trial approval australia biotech iot
Trinity Biotech Announces the World Health Organistion Approval Of TrinScreen™ HIV
Published: 2022-02-14 (Crawled : 14:30) - trinitybiotech.com
TRIB | $1.84 -0.81% 1.08% 3.1K
|
Health Technology
|
| O: 3.48%
H: 0.84%
C: -6.72%
health approval biotech iot hiv
Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV
Published: 2022-02-14 (Crawled : 13:30) - globenewswire.com
TRIB | $1.84 -0.81% 1.08% 3.1K
|
Health Technology
|
| O: 3.48%
H: 0.84%
C: -6.72%
health approval biotech iot hiv
Trinity Biotech Announces That Its Shareholders Have Approved All of the Four Resolutions That Were the Subject of the EGM Held on January 25, 2022
Published: 2022-01-25 (Crawled : 14:00) - biospace.com/
TRIB | $1.84 -0.81% 1.08% 3.1K
|
Health Technology
|
| O: 8.7%
H: 0.0%
C: -4.8%
ces biotech iot
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
Published: 2022-01-13 (Crawled : 13:30) - biospace.com/
EDSA | $4.4 1.25% -2.3% 570
|
Health Technology
|
| O: 6.49%
H: 0.0%
C: -13.11%
covid-19 drug approval covid test therapy biotech iot
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ADVM | $11.35 -2.24% -2.56% 68K
|
Health Technology
|
| O: -1.54%
H: 1.04%
C: -5.73%
treatment fda gene therapy drug granted preclinical orphan drug therapy biotech iot pre-clinical designation
FDA Approves XBiotech’s IND in RheumatologyLaunching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
XBIT | $8.11 -9.49% -10.48% 82K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: 0.0%
fda therapy antibody biotech iot
PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based CombinationInstitutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
PDSB | $2.72 -2.86% -3.32% 610K
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
phase 2 trial approval cancer biotech iot
Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
Published: 2021-09-29 (Crawled : 14:00) - biospace.com/
KRYS | $169.64 -0.27% -0.42% 150K
|
Health Technology
|
| O: 1.07%
H: 0.25%
C: -3.55%
fibrosis phase 1 biotech research iot trial approval cystic fibrosis
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.